Health

Bharat Biotech’s Covaxin will be 60% effective, tentatively to launch in September 2021

US FDA grants emergency use authorization to Regeneron COVID-19 antibody, also consumed by Trump

Unilever to launch COVID-19 killing mouthwash formula in India

WHO removes ‘remdesivir’ from prequalification list for treatment of COVID-19

Donald Trump Jr tests positive for COVID-19

Barring a man, village of 42 residents in Himachal Pradesh tested COVID-19 positive

EU likely to pay more than $10 Bn for Pfizer-BioNTech’s COVID-19 vaccine: Sources

WHO discourages usage of Gilead’s Remdesivir for COVID-19

Union Health Minister Harsh Vadhan assures COVID-19 vaccine will be ready in next three-four months

Kiran Mazumdar Shaw asks government to use CSR funds to vaccinate employees against COVID-19

Pfizer, BioNTech plan filing as vaccine reflect 95% effectivity

Haryana Minister Anil Vij volunteers for COVAXIN Phase 3 trial

YouTube to add link on COVID-19 vaccines to curb spread of misinformation

Pfizer on the verge to apply COVID-19 vaccine for emergency use authorization

US FDA approves 1st COVID-19 home-testing kit, gives results withing 30 minutes

Cipla signs licensing agreement with Multi G

Cipla Limited on Wednesday announced that it has signed a licensing agreement with Belgium-based firm, Multi G for the distribution of their COVID-19 Rapid Antibody test kit, across Emerging markets and Europe.